Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Gene Ther. 2015 Sep 25;22(10):496–505. doi: 10.1038/cgt.2015.49

Figure 5. ASCL1 suppression reduces neuroendocrine marker production and induces cell-cycle arrest in BON and H727 cells.

Figure 5

Treatment of BON and H727 cells with an ASCL1-specific siRNA reduced chromogranin A (CgA) and synaptophysin (SYP) levels, shown by Western blotting. Cells receiving the nonspecific-siRNA (NS-siRNA), exhibited no visible change in ASCL1, CgA or SYP levels relative to cells treated with Lipofectamine 2000® alone (no siRNA) (A). Concurrent with ASCL1 suppression following ASCL1-siRNA treatment, BON and H727 cell lines exhibited a reduction in cyclin B1 and D1 expression, and an increase in p21Waf1/Cip1 and p27Kip1 expression, as demonstrated by Western blotting, therefore suggesting the occurrence of cell-cycle arrest. Cells receiving the NS-siRNA experienced no effect on levels of any of these markers (B).